This study is being done to investigate the safety and efficacy of an investigational drug called ABT-719 on patients who are scheduled for a cardiac surgery and have at least one risk factor for developing Acute Kidney Injury (AKI). This study will evaluate the effect of ABT-719 on the prevention of AKI in patients undergoing cardiac surgery.
Subjects who are undergoing Cardio Pulmonary Bypass Surgery and have at least one additional risk factor which puts them at a high risk for Acute Kidney Injury.
Subjects participating in this study must have a screening visit to determine if they are eligible for the study. A medical history will be taken and routine blood tests will be done. A pregnancy test will be administered to women of childbearing ptential. If you are eligible you will be randomly assigned to a study group to receive a specific drug dosage or placebo prior to, during and after surgery. Tests and procedures will be performed at Day 0 (surgery) through Day 7, Day 30, Day 60 and Day 90.
Participation in this study lasts approximately 4 months and include up to 13 study visits to the research center. Up to 8 visits may occur while you are hospitalized.
For questions regarding this study contact Theresa Boley, APN at (217) 545-5000.
Stephen Hazelrigg, MD